Aimmune Therapeutics Inc buy tamam
Summary
This prediction ended on 01.01.19 with a price of €21.58. Massive losses of -31.36% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Aimmune Therapeutics Inc | - | - | - | - |
iShares Core DAX® | 2.275% | 4.627% | 18.839% | 16.367% |
iShares Nasdaq 100 | 6.015% | 2.007% | 23.636% | 35.232% |
iShares Nikkei 225® | 4.456% | 3.598% | 12.437% | -0.660% |
iShares S&P 500 | 4.061% | 2.876% | 23.447% | 38.511% |
Comments by tamam for this prediction
In the thread Aimmune Therapeutics Inc diskutieren
Aimmune Therapeutics achieves primary endpoint of phase 3 study treating patients with peanut allergy.
The data from the phase 3 trial using AR101 to treat peanut allergy is outstanding, and had met its specified endpoint necessary to be able be filed for FDA approval. Considering the medical need for patients who have a peanut allergy, I believe that Aimmune will not have a huge hurdle to cross in terms of receiving approval from the FDA. The reason is because AR101 could become the first oral treatment for those who have peanut allergy. This would be a huge milestone for Aimmune, because its pipeline is devoted to developing treatments for a host of different types of food allergies. Other allergy treatments being explored are those with egg allergy and walnut allergy. The goal for all these treatments is to reduce the amount of sensitivity one experiences when they come into contact with a food allergy. There is still a lot of risk involved with this stock. There is still a risk that the FDA might feel that the data is not adequate enough for approval of AR101. That means that this approval is not guaranteed to happen. Considering that the other programs in the pipeline are still in the pre-IND
stage, that makes the AR101 asset that much more important All is riding on the AR101 treatment, therefore all should be aware of the risk of taking a position into Aimmune Therapeutics. Having said that Aimmune is a good buy.
tamam stimmt am 22.02.2018 der Buy-Einschätzung der institutionellen Analysten mit dem Kursziel 55.5$ zu.
Stopped prediction by tamam for Aimmune Therapeutics Inc
Aimmune Therapeutics Inc
06.06.19
04.11.21
05.11.21